Akers Biosciences Inc (AKR)

 
This US company’s shares are traded by us as on the LSE. Income from them will not be treated as eligible for a reduced rate of tax. Learn more

AKR Share PerformanceMore

52 week high255.00 01/12/16
52 week low80.00 02/02/16
52 week change -5.00 (-4.76%)
4 week volume112,256 28/12/16

Media for (AKR)

Presenter: Ray, Akers, Co-Founder & Executive Chairman
28/07/2014
Presenter: Ray, Akers, Co-Founder & Executive Chairman
15/05/2014

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Akers Bio offering increased

Akers Biosciences says proceeds from its offering announced on 10 January are now expected to increase to $2,147,400, gros...

Issue of Equity

RNS Number: 0800U Akers Biosciences, Inc. 13 January 2017 13 January 2017 This announcement contains inside information Akers Biosciences, Inc. Issue of Equity Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ( " Akers Bio " or the "Company"), a developer of rapid health information technologies, announces that, further to the public offering announce...

Issue of Equity

RNS Number: 7349T Akers Biosciences, Inc. 10 January 2017 10 January 2017 This announcement contains inside information Akers Biosciences, Inc. Filing of Supplement to Form S-3 Registration Statement Issue of Equity Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ( " Akers Bio " or the "Company"), a developer of rapid health information technologies,...

Supplement to Form S-3 Registration Statement

RNS Number: 6004T Akers Biosciences, Inc. 09 January 2017 9 January 2017 This announcement contains inside information Akers Biosciences, Inc. Filing of Supplement to Form S-3 Registration Statement Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (" Akers Bio " or the "Company"), a developer of rapid health information technologies, announces that ...

Akers Bio resolutions passed at AGM

Akers Biosciences, a developer of rapid health information technologies, has confirmed that announces that all proposals m...

Result of AGM

RNS Number: 2858S Akers Biosciences, Inc. 19 December 2016 19 December 2016 Akers Biosciences, Inc. Result of Annual General Meeting Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers Bio" or the "Company"), a developer of rapid health information technologies, announces that all proposals made at the Annual General Meeting of the Company h...

Agreement with GNYHA for PIFA Heparin PF4 Test

RNS Number: 1677S Akers Biosciences, Inc. 19 December 2016 19 December 2016 This announcement contains inside information Akers Biosciences, Inc. 3-year Agreement with Greater New York Hospital Association for Heparin PF4 Rapid Test Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the "Company" or "Akers Bio"), a developer of rapid health infor...

US Distribution Agreement: Cholesterol Self-test

RNS Number: 6905Q Akers Biosciences, Inc. 01 December 2016 1 December 2016 This announcement contains inside information Akers Biosciences, Inc. US Distribution Agreement for Rapid Cholesterol Self-test Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the "Company" or "Akers Bio"), a developer of rapid health information technologies, has signed a ...

Equity Research (AKR)

Akers Biosciences Inc.
18/08/2016
Physiomics* (PYC.L) 0.04p £1.22m The computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials...
Akers Biosciences Inc.
11/08/2016
ValiRx (Val.L) 39p £4.37m The life science company, which focuses on clinical stage cancer therapeutic development has received regulatory approval for its VAL401 Phase IIB Clinical Trial in Georgia...

Latest discussion posts More

  • RNS : new PIFA agreement

    Looks like a potentially lucrative agreement with a group of up to 300 New York hospitals to introduce the PIFA ...
    19-Dec-2016
    gretel
  • Exciting RNS just out

    Worth noting in particular that First Check are a subsidiary of the mighty Alere ...
    1-Dec-2016
    gretel
  • New interview with CEO

    Gormally comes across extremely well. Certainly lots to look forward to. And more optimism about the $2m Chinese sale coming through this quarter, which will be great news ...
    16-Nov-2016
    gretel

Users' HoldingsMore

Users who hold Akers Biosciences Inc also hold..
LLOYDS GRP.26%
ID:ISIN:GB00B142G99420%
BP16%
NATIONAL GRID16%
BOS GLB HLDGS13%

Codes & Symbols

ISINUS00973E1029
SymbolsAKR, LSE:AKR, AKR.L, AKR:LN, LON:AKR, XLON:AKR